EIKOSpecialty Chemicals
Eiko Lifesciences Ltd — Cash Flow Statement
₹49.74
-3.48%
Eiko Lifesciences Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -7.37 Cr | -7.48 Cr | 4.00 Cr | -7.88 Cr | — |
| Issuance Of Debt | 2.76 Cr | — | — | 2.79 Cr | 1.56 Cr |
| Issuance Of Capital Stock | 4.35 Cr | 0.00 | 0.00 | 0.95 Cr | — |
| Capital Expenditure | -10.29 Cr | -0.35 Cr | -0.22 Cr | -0.15 Cr | — |
| End Cash Position | 11.78 Cr | 3.13 Cr | 0.61 Cr | 0.22 Cr | — |
| Other Cash Adjustment Outside Changein Cash | -1000.00 | -1000.00 | 1000.00 | 1000.00 | — |
| Beginning Cash Position | 13.35 Cr | 13.35 Cr | 0.22 Cr | 4.07 Cr | — |
| Changes In Cash | -1.57 Cr | -10.21 Cr | 0.40 Cr | -3.85 Cr | — |
| Financing Cash Flow | 6.96 Cr | 0.36 Cr | -4.70 Cr | 3.28 Cr | — |
| Net Other Financing Charges | 50000.00 | — | — | — | 1.00 |
| Interest Paid Cff | -0.16 Cr | -0.06 Cr | -0.15 Cr | -0.46 Cr | — |
| Net Common Stock Issuance | 4.35 Cr | 0.00 | 0.00 | 0.95 Cr | — |
| Common Stock Issuance | 4.35 Cr | 0.00 | 0.00 | 0.95 Cr | — |
| Net Issuance Payments Of Debt | 2.76 Cr | 0.43 Cr | -4.55 Cr | 2.79 Cr | — |
| Net Long Term Debt Issuance | 2.76 Cr | 0.43 Cr | -4.55 Cr | 2.79 Cr | — |
| Long Term Debt Issuance | 2.76 Cr | — | — | 2.79 Cr | 1.56 Cr |
| Investing Cash Flow | -11.44 Cr | -3.10 Cr | 0.87 Cr | 0.59 Cr | — |
| Net Other Investing Changes | 1.28 Cr | -0.62 Cr | 0.16 Cr | 0.11 Cr | — |
| Interest Received Cfi | 0.69 Cr | 0.38 Cr | 0.73 Cr | 0.64 Cr | — |
| Net Investment Purchase And Sale | -3.12 Cr | -3.04 Cr | 0.21 Cr | -26000.00 | — |
| Purchase Of Investment | -3.12 Cr | -3.96 Cr | — | -26000.00 | — |
| Net PPE Purchase And Sale | -10.29 Cr | 0.19 Cr | -0.22 Cr | -0.15 Cr | — |
| Operating Cash Flow | 2.92 Cr | -7.48 Cr | 4.22 Cr | -7.73 Cr | — |
| Taxes Refund Paid | -0.31 Cr | -0.15 Cr | 0.08 Cr | -0.21 Cr | — |
| Change In Working Capital | 0.32 Cr | -8.17 Cr | 3.10 Cr | -8.84 Cr | — |
| Change In Other Current Liabilities | 1.75 Cr | 0.21 Cr | -0.02 Cr | 0.04 Cr | — |
| Change In Other Current Assets | -3.47 Cr | -8.79 Cr | 1.40 Cr | -1.53 Cr | — |
| Change In Payable | 1.93 Cr | 0.85 Cr | -0.30 Cr | -0.55 Cr | — |
| Change In Inventory | -2.39 Cr | 0.68 Cr | 4.55 Cr | -5.39 Cr | — |
| Change In Receivables | 2.35 Cr | -1.12 Cr | -2.54 Cr | -1.15 Cr | — |
| Other Non Cash Items | -0.88 Cr | -0.31 Cr | -0.58 Cr | -0.17 Cr | — |
| Depreciation And Amortization | 0.74 Cr | 0.30 Cr | 0.63 Cr | 0.56 Cr | — |
| Depreciation | 0.74 Cr | 0.30 Cr | 0.63 Cr | 0.56 Cr | — |
| Gain Loss On Investment Securities | -0.01 Cr | 0.05 Cr | -0.03 Cr | -40000.00 | — |
| Gain Loss On Sale Of PPE | -1000.00 | -1000.00 | — | — | — |
| Net Income From Continuing Operations | 3.06 Cr | 0.81 Cr | 1.03 Cr | 0.94 Cr | — |
| Repayment Of Debt | — | 0.00 | -4.55 Cr | — | — |
| Long Term Debt Payments | — | 0.00 | -4.55 Cr | — | — |
| Dividends Received Cfi | — | 3000.00 | 0.00 | 40000.00 | 0.00 |
| Sale Of Investment | — | — | 0.21 Cr | — | 0.40 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Eiko Lifesciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.